Abstracts tagged "biologic response modifiers"

Abstract Number: 2055 • 2012 ACR/ARHP Annual Meeting
TEAM-Managed Care of Biological Patients At A Canadian Centre
Melissa Deamude¹, Dawn Heap², Melanie Kanellos², Debbie Kislinsky³, Kathy Kislinsky¹, Cynthia Mech⁴, Helena Ross¹, Peggy Saldanha³, Lauri Vanstone⁵, Kathleen Brown⁶ and William G. Bensen⁷, ¹Dr. William G. Bensen, Rheumatology Health Team, St. Joseph's Hospital Hamilton, Hamilton, ON, Canada, ²Dr. Bensen's Rheumatology Clinic, Hamilton, ON, Canada, ³Dr. William Bensen Rheumatology Clinic, Hamilton, ON, Canada, ⁴Dr. William G. Bensen, Rheumatology Health Team, Dr. Bensen's Rheumatology Clinic, Hamilton, ON, Canada, ⁵Dr. William Bensen Rheumatology Biologic Clinic, Rheumatology Health Team, Hamilton, ON, Canada, ⁶Dr. William Bensen Rheumatology Clinic, Rheumatology Health Team, St. Joseph's Hospital Hamilton, Hamilton, ON, Canada, ⁷Department of Medicine, Division of Rheumatology, St. Joseph's Hospital and McMaster University, Hamilton, ON, Canada
Background/Purpose: Managing complex arthritic patients with biologics is exacting and time consuming. As a result in January 2008 we established a separate biologic clinic with…
Abstract Number: 1004 • 2012 ACR/ARHP Annual Meeting
A Unique Single Nucleotide Polymorphism in the 3’ UTR of the MED29 Gene On Chromosome 19 Is Associated with the Clinical Outcome of Different Biologic Response Modifiers
Susanne Drynda¹, David Leesch², Marietta Gloetzner² and Joern Kekow², ¹Clinic of Rheumatology, Univ of Magdeburg, Clinic of Rheumatology, Vogelsang-Gommern, Germany, ²Clinic of Rheumatology, Univ of Magdeburg, Vogelsang-Gommern, Germany
Background/Purpose: Due to the wide range of highly specific and effective biologic response modifiers that are available today for the treatment of RA it has…
Abstract Number: 1839 • 2012 ACR/ARHP Annual Meeting
The Progression of the Rate of Biologic Initiation in Early Rheumatoid Arthritis Is Constant Over the First 5 Years in the Espoir Cohort
Stéphanie Emilie¹, Cécile Gaujoux-Viala², Benjamin Granger³, Anne-Christine Rat⁴, Bernard Combe⁵ and Bruno Fautrel⁶, ¹Paris 6,Pierre and Marie Curie University, AP-HP, Pitié-Salpêtrière Hospital, Department of Rheumatology, Paris, France, ²Paris 6 – Pierre et Marie Curie University; Rheumatology, Pitié-Salpêtrière Hospital, Paris, France, ³Biostatistics - GRC08-EEMOIS, Université Pierre et Marie Curie - Paris 6 ; AP-HP, Paris, France, ⁴CHU Nancy, Clinical Epidemiology and Evaluation, Université de Lorraine, Paris Descartes University, APEMAC, EA 4360, Nancy, France, ⁵Rheumatology, Hopital Lapeyronie, Montpellier, France, ⁶Rheumatology / GRC08-EEMOIS, APHP-Pitie Salpetriere Hospital / UPMC, Paris, France
Background/Purpose: The European League Against Rheumatism recommends tight control of rheumatoid arthritis (RA). However, tight control of RA may depend on several factors, including patient…
Abstract Number: 782 • 2012 ACR/ARHP Annual Meeting
Anti-TNF Therapy Slows Radiographic Progression of Ankylosing Spondylitis
Nigil Haroon¹, Robert D. Inman², Thomas J. Learch³, Michael H. Weisman⁴, Michael M. Ward⁵, John D. Reveille⁶ and Lianne S. Gensler⁷, ¹Medicine/Rheumatology, University Health Network, Toronto Western Research Institute, University of Toronto, Toronto, ON, Canada, ²Dept of Medicine/Rheumatology, Toronto Western Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ³Cedars-Sinai, Los Angeles, CA, ⁴Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁵Bldg 10 CRC Rm 4-1339, NIAMS/NIH, Bethesda, MD, ⁶Internal Medicine/Rheumatology, Univ of Texas Health Science Center at Houston, Houston, TX, ⁷Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA
Background/Purpose: The influence of anti-TNF therapy on radiographic progression in ankylosing spondylitis (AS) is not well established. We studied this effect on radiographic progression in…
Abstract Number: 1827 • 2012 ACR/ARHP Annual Meeting
Factors That Impact Work Productivity in the Preserve Trial: A Randomized Controlled Trial of Combination Etanercept-Methotrexate Therapy in Patients with Moderately Active Rheumatoid Arthritis
Vibeke Strand¹, Thomas V. Jones², Wenzhi Li³, Andrew S. Koenig⁴ and Sameer Kotak⁵, ¹Adjunct, Division of Immunology / Rheumatology, Stanford University, Portola Valley, CA, ²Inflammation Specialty Care, Pfizer, Inc, Collegeville, PA, ³Pfizer Inc., Collegeville, PA, ⁴Specialty Care Business Unit, Pfizer Inc., Collegeville, PA, ⁵Specialty Care, Pfizer Inc., New York, NY
Background/Purpose: Active joint inflammation and structural damage in patients with rheumatoid arthritis (RA) often result in impaired physical function and ultimately work disability.1,2 Lost productivity…
Abstract Number: 762 • 2012 ACR/ARHP Annual Meeting
Potentially Fatal Pulmonary Complications in Systemic Juvenile Idiopathic Arthritis
Yukiko Kimura¹, Jennifer E. Weiss², Kathryn L. Haroldson¹, Tzielan C. Lee³, Marilynn G. Punaro⁴, Sheila K. Feitosa de Oliveira⁵, C. Egla Rabinovich⁶, Meredith P. Riebschleger⁷, Jordi Anton⁸, Peter R. Blier⁹, Valeria Gerloni¹⁰, Melissa M. Hazen¹¹, Elizabeth Kessler¹², Karen Onel¹³, Murray H. Passo¹⁴, Robert M. Rennebohm¹⁵, Carol A. Wallace¹⁶, Patricia Woo¹⁷, Nico M. Wulffraat¹⁸ and CARRAnet Investigators¹⁹, ¹Pediatric Rheumatology, JM Sanzari Children's Hospital, Hackensack University Medical Center, Hackensack, NJ, ²Pediatric Rheumatology, Joseph M Sanzari Children’s Hospital, Hackensack University Medical Center, Hackensack, NJ, ³Pediatric Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁴Pediatric Rheumatology, Texas Scottish Rite Hospital, Dallas, TX, ⁵Pediatric Rheumatology, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, ⁶Pediatric Rheumatology, Duke University Medical Center, Durham, NC, ⁷Pediatric Rheumatology & Health Services Research, University of Michigan, Ann Arbor, MI, ⁸Rheumatology, Hospital Sant Joan de Deu, Barcelona, Spain, ⁹Pediatrics, Baystate Children's Hospital, Springfield, MA, ¹⁰Pediatric Rheumatology, Gaetano Pini Chair of Rheum, Milan, Italy, ¹¹Division of Immunology, Boston Children's Hospital, Boston, MA, ¹²Pediatric Rheumatology, Medical College of Wisconsin, Milwaukee, WI, ¹³Pediatric Rheumatology, University of Chicago Hospitals, Chicago, IL, ¹⁴Pediatrics, Medical University of South Carolina, Charleston, SC, ¹⁵Pediatric Rheumatology, Alberta Children's Hospital, University of Calgary, Calgary, AB, Canada, ¹⁶Pediatrics, Seattle Childrens Hospital, Seattle, WA, ¹⁷Division of Infection and Immunity, University College London, London, United Kingdom, ¹⁸Pediatric Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ¹⁹Durham
Background/Purpose: Systemic Juvenile Idiopathic Arthritis (sJIA) is characterized by fevers, rash and arthritis, for which IL1 and IL6 inhibitors appear to be effective. Pulmonary artery…
Abstract Number: 1830 • 2012 ACR/ARHP Annual Meeting
Drugs Are the Major Cost Driver of Rheumatoid Arthritis As Soon As the First Year of the Disease: An Economic Analysis Based On the Espoir Cohort Data
Bruno Fautrel¹, Sandy Lucier², Georges Haour², Hassani Maoulida², Stephanie Harvard¹, Alain Saraux³, Xavier Mariette⁴, Francis Guillemin⁵, Isabelle Durand-Zaleski² and Karine Chevreul², ¹Rheumatology / GRC08-EEMOIS, APHP-Pitie Salpetriere Hospital / UPMC, Paris, France, ²APHP - URC Eco, Paris, France, ³Department of rheumatology and unit of immunology (EA 2216), Université Brest Occidentale, Brest, France, ⁴Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France, ⁵Hopitaux de Brabois, Nancy, France
Background/Purpose: Many studies have explored the economic burden of established RA but few data are available about the determinants of costs in early rheumatoid arthritis…
Abstract Number: 692 • 2012 ACR/ARHP Annual Meeting
A Phase 1 Multicenter, Open-Label Study of MEDI-546, a Human Anti-Type I Interferon Receptor Monoclonal Antibody, in Adults with Scleroderma
Avram Z. Goldberg¹, Thomas D. Geppert², Elena Schiopu³, Tracy M. Frech⁴, Vivien M. Hsu⁵, Robert W. Simms⁶, Stanford L. Peng⁷, Yihong Yao⁸, Nairouz Elgeioushi⁹, Bing Wang¹⁰, Linda Chang¹¹ and Stephen Yoo¹², ¹Div of Rheumatology, North Shore-LIJ Health System, Lake Success, NY, ²Metroplex Clinical Research Center, LLC, Dallas, TX, ³Rheumatology/Internal Medicine, University of Michigan, Ann Arbor, MI, ⁴Internal Medicine-Division of Rheumatology, University of Utah School of Medicine, SLC, UT, ⁵Rheumatology, RWJ Med Schl Scleroderma Prog, New Brunswick, NJ, ⁶Rheumatology, Boston University School of Medicine, Boston, MA, ⁷Department of Rheumatology, Benaroya Research Institute at Virginia Mason Medical Center, Seattle, WA, ⁸Translational Sciences, MedImmune, Gaithersburg, MD, ⁹Medical Biostatistics, MedImmune, Gaithersburg, MD, ¹⁰Clinical Pharmacology and DMPK, Medimmune, Mountain View, CA, ¹¹Translational Sciences, MedImmune, Hayward, CA, ¹²Clinical Development, MedImmune, Gaithersburg, MD
Background/Purpose: Type I interferons (IFNs) have been implicated in the pathogenesis of scleroderma. This phase 1 study evaluated safety, pharmacokinetics (PK), pharmacodynamics, and immunogenicity of…
Abstract Number: 1817 • 2012 ACR/ARHP Annual Meeting
The Role of Repeating Tuberculin Skin Tests During Biologic Therapy
Joseph R. Lutt¹ and Kevin L. Winthrop², ¹Colorado Center for Arthritis & Osteoporosis, Boulder, CO, ²Dept of Infectious Disease, Oregon Health & Science University, Portland, OR
The Role of Repeating Tuberculin Skin Tests during Biologic TherapyBackground/Purpose: Prior to starting biologic therapy, it is recommended that all patients be screened for tuberculosis…
Abstract Number: 495 • 2012 ACR/ARHP Annual Meeting
Comparison of Discontinuation Rates by Biologic Since 1998 in US Patients with Rheumatoid Arthritis
Sofia Ramiro¹, Frederick Wolfe², David J. Harrison³, George Joseph³, David H. Collier³, Désirée van der Heijde⁴, Robert Landewé⁵ and Kaleb Michaud⁶, ¹Clinical Immunology & Rheumatology, Academic Medical Center, University of Amsterdam, The Netherlands and Hospital Garcia de Orta, Almada, Portugal, ²National Data Bank for Rheumatic Diseases, Wichita, KS, ³Amgen Inc., Thousand Oaks, CA, ⁴Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁵Clinical Immunology & Rheumatology, Academic Medical Center, University of Amsterdam and Atrium Medical Center, Heerlen, Netherlands, ⁶Rheumatology, National Data Bank for Rheumatic Diseases & University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Since discontinuation may be a surrogate for ineffectiveness, we measured rates and reasons for biologic discontinuation in a real-world setting. Methods: From 1998 to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].